Introduction {#section5-1758835919899852}
============

Cancer has been reported among the leading causes of morbidity and mortality worldwide, with the number of cases expected to continue to rise.^[@bibr1-1758835919899852]^ Although treatment efficacy is improving, the development of malnutrition, induced by the tumour or treatment side effects, remains a frequent and important barrier to achieving the best possible outcomes.^[@bibr2-1758835919899852]^ Depending on the cancer diagnosis and stage, malnutrition has been estimated occurring in approximately 30--60% of cancer patients,^[@bibr3-1758835919899852][@bibr4-1758835919899852][@bibr5-1758835919899852][@bibr6-1758835919899852][@bibr7-1758835919899852]--[@bibr8-1758835919899852]^ and is associated with increased morbidity and mortality.^[@bibr9-1758835919899852]^ Malnutrition in cancer patients can be referred to as cachexia, which is considered a result of complex interplay between underlying disease, disease-related metabolic alterations and, in some cases, the reduced availability of nutrients (due to reduced intake, impaired absorption or increased losses, or a combination of these). Malnutrition is a state of nutrition in which a deficiency or excess (or imbalance) of energy, protein, and other nutrients causes measurable adverse effects on tissue/body form (body shape, size, and composition) and function, and clinical outcomes. Reduced nutrient availability, however, may be a component of, and play a role in, the pathogenesis of cachexia. Notably, cachexia is not always present in all malnourished patients, whereas all cachectic patients suffer from malnutrition.^[@bibr10-1758835919899852]^ Research suggests that around 20--30% of cancer patients may die due to consequences of malnutrition, rather than cancer itself.^[@bibr9-1758835919899852]^

The European Society for Clinical Nutrition and Metabolism (ESPEN) has published guidelines and a position paper recommending nutritional screening in all cancer patients.^[@bibr11-1758835919899852]^ In addition, countries such as Scotland and the Netherlands have established mandatory screening for malnutrition in cancer patients.^[@bibr2-1758835919899852]^ More recently, the Italian Ministry of Health published the official guidelines for the nutritional pathways for cancer patients, in collaboration with the joint Working Group by the Italian Association of Medical Oncology, the Italian Society of Artificial Nutrition and metabolism, and the Italian Federation of Volunteer-based Cancer Organizations.^[@bibr12-1758835919899852]^

Despite all these recommendations, malnutrition often remains overlooked^[@bibr13-1758835919899852]^ and even if diagnosed, is untreated in about 50% of cases.^[@bibr4-1758835919899852],[@bibr14-1758835919899852]^ Importantly, there is increasing evidence supporting how clinical nutrition (CN) intervention can be associated with decreased therapy toxicity, improved relative-dose intensity (RDI), with fewer treatment delays and dose modifications.^[@bibr15-1758835919899852],[@bibr16-1758835919899852]^ As a result, especially when it is initiated at the time of diagnosis or as soon as nutritional risk is detected, CN offers the potential to improve cancer patients' outcomes, such as quality of life and overall survival.^[@bibr17-1758835919899852]^ Despite the increasing awareness of the negative impact of malnutrition on clinical outcomes in cancer patients, the understanding of malnutrition rates, as well as the use of CN in the real-world setting, is lacking. Our overall objective in this research investigation was to describe the management of malnutrition among cancer patients in current clinical practice, using real-world data from large administrative healthcare datasets from three European countries. Several analytical methodologies were applied to characterize and demonstrate meaningful insights into different aspects of cancer patients' care. Specifically, (a) diagnosis, frequency, and rates of malnutrition, and (b) the use of CN in hospitalized cancer patients and in the homecare setting were examined.

Methodology and data analysis {#section6-1758835919899852}
=============================

The original research investigations were conducted separately for each country. The methodology and data analysis for each study in each country are described separately.

France {#section7-1758835919899852}
------

Malnutrition diagnosis frequency and timing were investigated, based on data from the French Hospital database PMSI (Program for the Medicalization of Information Systems), and Medicine, Surgery (Chirurgie), Obstetrics. The database contained information on reported diagnosis, procedures and included mean values for drugs used in each diagnosis group.^[@bibr18-1758835919899852]^ The study period ranged from 1 January 2013 to 31 December 2016 and inclusion criteria were: a first gastrointestinal (GI; colon--rectal--anal, liver/biliary tract, pancreas, stomach, and esophagus) cancer-related hospital stay, as defined by the algorithm for attribution of hospitalizations related to cancer developed jointly by the Hospital Information Technology Agency, the National Cancer Institute (INCA) and representatives of public and private hospitals from the INCA during the study period 2013--2016. The index date was defined as the date of the first cancer-related hospitalization. All patients without any GI-cancer-related hospitalization were included in the 2 years preindex date ([Table 1](#table1-1758835919899852){ref-type="table"}). Multiple hospitalizations were possible for each patient. Malnourished patients were required to have an International Statistical Classification of Diseases and Related Health Problems (ICD)-10 malnutrition diagnosis code and an accompanying diagnosis code of at least moderate or severe malnutrition in the PMSI database \[as defined by the French Health Authorities recommendations (HAS 2007) and the associate diagnosis codes (DAS) for moderate (E440) and severe (E43) malnutrition\]. Patients were grouped into three diagnosis categories: (0) no malnutrition diagnosis in the study period; (1) malnutrition diagnosis at first GI-cancer-related hospitalization (early diagnosis); and (2) malnutrition diagnosis after first GI-cancer-related hospitalization (late diagnosis). The frequency of the diagnosis in each category was also assessed.Germany

###### 

Main characteristics for each study.

![](10.1177_1758835919899852-table1)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study parameters                           France                                                                                                                                                                                                                                                         Germany                                                                                                                                                                                           Italy
  ------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Data source                                French hospital database, PMSI                                                                                                                                                                                                                                 70 SHI organizations                                                                                                                                                                              Integrated administrative database from 10 Italian LHUs

  Number of patients included                570,727                                                                                                                                                                                                                                                        4642                                                                                                                                                                                              58,468

  Healthcare setting                         Hospital                                                                                                                                                                                                                                                       Homecare                                                                                                                                                                                          Hospital and homecare

  Study period                               1 January 2013--31 December 2016                                                                                                                                                                                                                               1 January 2010--31 December 2016                                                                                                                                                                  1 January 2009--31 December 2015

  Definition of index date                   Date of first cancer-related hospitalization                                                                                                                                                                                                                   Date of an initial prescription of guideline-recommended pharmacotherapy (pursuant to guidelines of stage III and stage IV cancer) or the first HPN prescription                                  Date of first diagnosis of metastasis or first CN prescription clinical nutrition after diagnosis

  Pre- and postindex observation time        No cancer-related hospital stay 2 years preindex                                                                                                                                                                                                               3 years before the first HPN                                                                                                                                                                      12 months pre- and postindex

  Cancer population and inclusion criteria   As defined by the algorithm for attribution of hospitalizations related to cancer, developed jointly by the ATIH, the INCA, and representatives of public and private hospitals from the National Cancer Institute, patients with GI cancers were included:\   As defined in ICD-10 CM Coding Chapter 'C', the study population included deceased stage III/IV cancer patients with initial therapy pursuant to guidelines of stage III and stage IV cancers:\   As defined in ICD-9-CM diagnoses codes 140.XX to 209.XX and 235.XX to 239.XX and first occurrence of a metastasis diagnosis (ICD-9-CM codes 196.XX to 199.XX) study population included:\
                                             (1) CRC\                                                                                                                                                                                                                                                       (1) H&N: cetuximab without radiation\                                                                                                                                                             (1) H&N\
                                             (2) Liver/biliary tract\                                                                                                                                                                                                                                       (2) CRC: bevacizumab or cetuximab\                                                                                                                                                                (2) GI\
                                             (3) Pancreas\                                                                                                                                                                                                                                                  (3) Ovarian: carboplatin and paclitaxel with or without bevacizumab\                                                                                                                              (3) Respiratory\
                                             (4) Stomach\                                                                                                                                                                                                                                                   (4) Pancreas: gemcitabine, if there was no surgery 3 months before\                                                                                                                               (4) Genitourinary\
                                             (5) Esophagus                                                                                                                                                                                                                                                  (5) Gastric: diagnosis directly followed by a prescription of parenteral or enteral nutrition                                                                                                     (5) Haematology

  Malnutrition assessment                    ICD-10 malnutrition diagnosis code and an accompanying diagnosis code of at least moderate or severe malnutrition in the PMSI database                                                                                                                         ATC codes for prescription of HPN; and as defined in ICD-10 diagnostic code for cachexia                                                                                                          ATC codes:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              (1) B05 blood substitutes and perfusion solutions\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              (2) B05B i.v. solutions\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              (3) B05BA solutions for parenteral nutrition \[note: glucose at low concentrations (\<20%) was excluded\]\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ICD-9-CM codes:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              (1) 96.6 enteral infusion of concentrated nutritional substances\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              (2) 99.15 parenteral infusion of concentrated nutritional substances

  Study research outcomes                    Rate, frequency, and timing of malnutrition stratified by GI cancer type and patient profile                                                                                                                                                                   (1) Frequency and timing of HPN use stratified by cancer type\                                                                                                                                    (1) Proportion of nonmetastatic and metastatic patients receiving CN\
                                                                                                                                                                                                                                                                                                            (2) Proportion of patients with cachexia (general physical wasting with loss of weight and muscle mass due to a disease)                                                                          (2) Time from metastasis diagnosis to initiation of CN\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              (3) Time from initiation of CN to death
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ATC, Anatomical Therapeutic Chemical Classification; ATIH, Hospital Information Technology Agency; CM, clinical modification; CN, clinical nutrition; CRC, colorectal cancer; GI, gastrointestinal; H&N, head and neck; HPN, home parenteral nutrition; ICD, International Classification of Diseases and Related Health Problems; INCA, National Cancer Institute; i.v., intravenous; LHU, Local Health Units; PMSI, Program for the Medicalization of Information Systems; SHI, Statutory Health Insurance.

Data from over 4 million insured individuals from approximately 70 Statutory Health Insurance organizations, including information on services, prescriptions, and procedures were used to select patients who died in the study period from 1 January 2010 to 31 December 2016 and had a diagnosis of head and neck (H&N), colorectal (CRC), ovarian, pancreatic, and gastric cancers. The study population included deceased patients with locally advanced carcinoma stage III or metastatic stage IV cancers. The index date was defined as the date of an initial prescription of guideline-recommended pharmacotherapy or the first PN prescription administered at home (home parenteral nutrition, HPN). A 3-year preindex observation period was required before the first prescription ([Table 1](#table1-1758835919899852){ref-type="table"}). The study described the frequency and timing of HPN use stratified by cancer type. Furthermore, the study identified the proportion of patients with cachexia (as defined by ICD-10 diagnosis codes) among patients who received HPN compared with those who did not receive HPN.

Italy {#section8-1758835919899852}
-----

The use of CN, defined as enteral nutrition (EN) with or without parenteral nutrition (PN) in oncology patients was assessed, based on an integrated administrative database using data from 10 Italian Local Health Units (LHUs). The administrative database for healthcare resource use included information from a pharmaceutical database, a hospitalization database, laboratory tests, diagnostic tests and specialist visits database. The database covers 5.9 million people from various regions in the northern, central and southern Italy, representing around 10% of the total Italian population.

The study period was from 1 January 2009 to 31 December 2015. All patients with a diagnosis of H&N, gastrointestinal, respiratory, genitourinary, or haematologic malignancies defined by ICD-9-CM during the study period and a 12-month, available, pre- and postindex observation period were included. ICD-9 disease classification codes were used in Italy because the observation period started in January 2009. The new ICD-10 CM coding system took effect from October 2015. The index date was defined as the date of the first metastasis diagnosis or the first prescription of CN after diagnosis. Selected Anatomical Therapeutic Chemical Classification (ATC) codes {A11BA: oral multivitamins, plain; B05BA: solutions for parenteral nutrition \[glucose at low concentrations (\<20%) were excluded\]; B05XB: amino acids \[intravenous (i.v.) solution additives\]; B05XC: vitamins (i.v. solution additives)} in combination with ICD-9-CM procedural codes for enteral/parenteral infusion of concentrated nutritional substances (ICD-9-CM 96.6; ICD-9-CM 99.15) and at-home nutritional product prescriptions were used to define CN ([Table 1](#table1-1758835919899852){ref-type="table"}). Patients were divided into three cohorts: metastatic with CN, metastatic without CN, and patients without metastatic disease. The proportion of nonmetastatic and metastatic patients receiving CN was assessed. In addition, the time from metastasis diagnosis to the initiation of CN intervention and the time from initiation of CN to death were further investigated.

Statistical analysis {#section9-1758835919899852}
====================

High-dimensional statistically relevant propensity-score matching (PSM)-based analysis was used to match patients by age, sex, and comorbidities, and were used as variables in the regression analysis. PSM had to show significant differences in cancer patients with and without CN. PSM reduces the bias due to confounding variables and achieves better comparability between the matched groups.

Descriptive statistical analysis of correlations was based on individual level data. Statistical parameters included: mean, standard deviation, median, minimum/maximum, with 95% confidence interval (CI), and *p* value \< 0.05 was considered statistically significant. All statistical analyses were performed using STATA SE, R (statistical software, StataCorp LLC, College Station, TX, U.S.), and the Microsoft Excel application.

Results {#section10-1758835919899852}
=======

The results are presented separately for each study.

France {#section11-1758835919899852}
------

The study population identified 570,727 GI cancer patients with a first related hospital stay between 2013 and 2016. The distribution of patients by cancer types is shown in [Figure 1](#fig1-1758835919899852){ref-type="fig"}.

![Distribution of GI cancer patients by type of cancer.\
GI, gastrointestinal.](10.1177_1758835919899852-fig1){#fig1-1758835919899852}

Malnutrition diagnosis at first hospitalization was reported in the PMSI database for 10% of patients with GI cancer, 13% were diagnosed after the first hospitalization and 77% had no diagnosis of malnutrition during the study period. The proportion of patients for whom malnutrition was reported ranged from 14% in CRC cancer patients to 38% in patients with pancreatic cancer. For all types of cancer, the 2016 PMSI data reports about 1.2 million cancer patients in France, of which one third are reported with a malnutrition code (as defined by ICD-10 criteria), which is substantially lower than previous prevalence estimates in the available literature^[@bibr4-1758835919899852]^ ([Figure 2](#fig2-1758835919899852){ref-type="fig"}).

![Comparison between prevalence estimates of malnutrition previously reported in the literature and frequencies found in the French Program for the Medicalization of Information Systems database.\
PMSI, Program for the Medicalization of Information Systems.](10.1177_1758835919899852-fig2){#fig2-1758835919899852}

Germany {#section12-1758835919899852}
-------

The study population included 4642 patients \[most patients were male (59%); age, mean (95% CI): 67 (62.9--71.6) years\] with late stage III or IV cancer. A total of 343 had H&N, 1966 CRC, 327 ovarian, 1406 pancreatic, and 600 gastric cancer ([Table 2](#table2-1758835919899852){ref-type="table"}). Across five cancer types, the proportion of patients who received HPN was 16%, on average, with the lowest rates in H&N (12.5%), followed by CRC and pancreatic cancer (14.8% and 14.9%, respectively), ovarian cancer (18.9%), and the highest rates in gastric cancer with 25.5% ([Table 2](#table2-1758835919899852){ref-type="table"}). The time from initiation of cancer treatment to initiation of HPN varied widely by type of cancer, with approximately 6 months for gastric and more than 2 years for ovarian cancer, with an average of 337 days delay across five cancer types ([Table 2](#table2-1758835919899852){ref-type="table"}). The data suggest that patients who received HPN survived longer (range: +29 days for CRC and up to +118 days in gastric cancer) than those patients who did not receive HPN ([Table 2](#table2-1758835919899852){ref-type="table"}).

###### 

Average time delay until HPN initiation and period until death between patients who received and did not receive HPN by cancer type.

![](10.1177_1758835919899852-table2)

                                                                                                                               Head and neck   Colorectal    Ovarian      Pancreatic    Gastric
  ---------------------------------------------------------------------------------------------------------------------------- --------------- ------------- ------------ ------------- -------------
  Patient sample                                                                                                               343             1966          327          1406          600
  Number of patients received HPN (%)                                                                                          43 (12.5%)      290 (14.8%)   53 (18.9%)   209 (14.9%)   153 (25.5%)
  **The time delay from the initiation of cancer treatment to initiation of HPN**                                                                                                       
  Mean duration until HPN initiation per patient (days)                                                                        266.6           394.5         625.8        200.1         195.7
  **Patients who received HPN survived longer than patients who did not receive HPN**                                                                                                   
  A: mean period until death per patient who received HPN (days)                                                               376.7           500.7         760.1        282.9         355.5
  B: mean period until death per patient who did not receive HPN (days)                                                        295.7           472.4         718.8        209.3         237.7
  C: difference (Δ = A -- B) between mean periods until death among patients who received HPN and did not receive HPN (days)   Δ 81            Δ 29          Δ 41         Δ 84          Δ 118

HPN, home parenteral nutrition.

Descriptive data analysis across five cancer types showed that initiation of HPN was predominantly an 'end of life' intervention, with time to death of approximately 3 months. To put these findings in perspective, the proportion of cachexia in patients with CRC was nearly identical between patients who received HPN (45%) and those who did not receive it (47%).

Italy {#section13-1758835919899852}
-----

Out of 69,000 metastatic cancer patients, 8.4% received CN; among these, 89% had PN. In a subanalysis of 190,000 patients without metastasis, 3.11% received CN ([Figure 3](#fig3-1758835919899852){ref-type="fig"}).

![Use of clinical nutrition in metastatic and nonmetastatic cancer patients in the Italian cohort.](10.1177_1758835919899852-fig3){#fig3-1758835919899852}

Among metastatic patients with selected cancers (H&N, gastrointestinal, respiratory, genitourinary, or haematological: *n* = 58,468), 8.2% received CN, of which only 11% had the diagnosis of malnutrition reported. The average time between the diagnosis of metastasis and first use of CN was 6.6 months.

Approximately 35% of patients started CN in the first month after diagnosis of metastasis ([Figure 4](#fig4-1758835919899852){ref-type="fig"}, left panel). For approximately 18% of patients, more than 1 year passed between metastasis diagnosis and the first use of CN. The average time between the first use of CN and death was 3.5 months. Furthermore, approximately half of metastatic patients received CN just before death, and this pattern was observed across all cancer types. A total of 15% of metastatic cancer patients received CN more than 7 months before they deceased ([Figure 4](#fig4-1758835919899852){ref-type="fig"}, right panel).

![Percentage of patients by month from diagnosis of metastasis to clinical nutrition treatment (left panel) and from clinical nutrition treatment to death (right panel).](10.1177_1758835919899852-fig4){#fig4-1758835919899852}

Discussion {#section14-1758835919899852}
==========

These studies investigated different aspects of current practices and use of CN in oncology, based on the real-world administrative datasets from three European countries (France, Germany, and Italy), using different analytical methodologies. The data provide a broad overview of different characteristics, including actual clinical practices, areas with existing clinical unmet needs, and a potential for improvement in treating cancer-related malnutrition.

In general, the study results from all three countries suggest that the diagnosis of malnutrition in clinical practice occurs later and less frequently than what is recommended according to the current clinical guidelines^[@bibr2-1758835919899852],[@bibr19-1758835919899852]^ or what is generally reported in the literature.^[@bibr4-1758835919899852],[@bibr14-1758835919899852]^ Late or lack of diagnosis of malnutrition can reduce the potential benefits of earlier nutritional intervention in cancer patients.^[@bibr15-1758835919899852][@bibr16-1758835919899852]--[@bibr17-1758835919899852],[@bibr20-1758835919899852],[@bibr21-1758835919899852]^ More up-to-date data would be necessary to understand current adherence to the recently published ESPEN guidelines for clinical nutritional care in patients with cancer.^[@bibr2-1758835919899852]^ Moreover, the data showed that the diagnostic procedures of malnutrition may not be optimal in hospital and homecare settings, given that the reported proportion of patients with a diagnosis of malnutrition was found to be considerably lower than expected. The currently available literature suggest that the general prevalence of malnutrition is about 30--60% in cancer patients^[@bibr4-1758835919899852][@bibr5-1758835919899852]--[@bibr6-1758835919899852],[@bibr8-1758835919899852],[@bibr14-1758835919899852]^ and can be significantly higher in specific cancers (85% in pancreatic cancers).^[@bibr22-1758835919899852]^ The low rates of reported malnutrition diagnosis in France, where treatment is mandatory, the low utilization of HPN in Germany, and the very low proportion of patients receiving CN in Italy indicate that malnutrition in the real-world clinical setting is underdiagnosed or totally overlooked and that, as a result, appropriate CN therapy remains underutilized. This conclusion is also supported by other published studies.^[@bibr4-1758835919899852]^ Diagnostic procedures for malnutrition can be considerably improved, in line with recent calls for routine screening.^[@bibr23-1758835919899852]^ These data support the importance for the European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO) to include in future guidelines the proactive and standardized use of validated nutritional screening and assessment tools for all cancer patients or patients with cancer known to be at risk for malnutrition with or without weight loss.

Early intervention with nutritional supplementation has been reported to halt progression of malnutrition and may improve outcomes in some patients.^[@bibr15-1758835919899852][@bibr16-1758835919899852]--[@bibr17-1758835919899852],[@bibr20-1758835919899852],[@bibr21-1758835919899852]^ However, the results from Italy and Germany showed that CN was often used as an end-of-life intervention, as it was used 3--4 months or shortly just before death. The late initiation of CN represents a lost opportunity to improve patients' care.^[@bibr24-1758835919899852]^ This is also in accordance with the position paper from the European School of Oncology Task Force has highlighted that 'early detection of malnutrition and cachexia will be increasingly important in the hope that timely intervention can improve both patient-centred and oncology outcomes.'^[@bibr25-1758835919899852]^ In addition to the importance of improving cancer patients' outcomes, it is of great relevance from an economic perspective, given that the financial impact of malnutrition has been estimated as very high.^[@bibr26-1758835919899852][@bibr27-1758835919899852][@bibr28-1758835919899852][@bibr29-1758835919899852]--[@bibr30-1758835919899852]^

However, further studies on the patterns of CN use, specifically investigating the clinical benefits of early interventions and factors that influence the practical implementation of these aspects, are required to encourage the best practices for screening and treatment of malnutrition. Some countries have already established mandatory screening procedures for malnutrition in cancer patients. Future clinical and health economic research may include comparative studies to established current prevalence rates and treatment of malnutrition between countries with and without mandatory screening policies.

Limitations {#section15-1758835919899852}
===========

There are several limitations that should be kept in mind when interpreting the findings from these studies in each country. The primary limitation for each study was that the data from administrative datasets were not collected specifically to be used in health-related scientific research and lacked detailed clinical information. Secondly, the data generated from the three large national databases in France, Germany, and Italy were not merged, as the datasets were not directly comparable due to different design, methodological approaches used, and only descriptive and exploratory analyses performed. Furthermore, the additional subanalyses stratified by each cancer type conducted in each country to understand the use of healthcare resources and clinical outcomes in patients receiving CN, compared with those who not receiving CN, were not included in this assessment and will be published separately. Considering these limitations, this research analysis still holds its significance with multifaceted and compelling insights derived from this first look at the real-world application of CN in oncology allowed the characterization of several interesting aspects within current clinical practice. These aspects may be fundamental to further understand the potential clinical and economic benefits of CN in oncology and may also stimulate the design of large prospective clinical nutrition trials.

Conclusion {#section16-1758835919899852}
==========

Multiple investigations across three European countries consistently showed that in the real-world clinical practice cancer-related malnutrition is underdiagnosed, under-reported and undertreated. CN is often prescribed as an end-of-life intervention or not prescribed at all for cancer patients at nutritional risk.

Despite several international recommendations for routine and early nutritional screening, appropriate CN use remains challenging and current clinical practice may not allow the achievement of optimal oncologic outcomes for cancer patients. Improving the awareness of malnutrition and generating further evidence to evaluate clinical and economic benefits of CN as a supportive therapy are critical priorities to optimize cancer patients' care.
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